RxDoctor Payments Data

Jeffrey Stone, MD

Family Medicine · Canton, GANPI 1154410538

Payments from drug & device makers

$7,384in general payments, 2019–2025

Across 434 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$917
  • Sanofi-aventis U.S. LLC$612
  • AstraZeneca$529
  • AbbVie$511
  • Pfizer$349
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$7,360100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,384 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$77,523
Medicare patients
255
Services billed
1,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$31,597
MounjaroTirzepatide18$28,169
OzempicSemaglutide26$24,539
EliquisApixaban15$20,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,346
TrulicityDulaglutide12$11,139
FarxigaDapagliflozin Propanediol16$10,893
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,540
SynthroidLevothyroxine Sodium17$2,029
Atorvastatin Calcium202$1,219
Nebivolol Hcl12$1,206
Levothyroxine Sodium109$890
Omeprazole66$728
Rosuvastatin Calcium106$719
LantusInsulin Glargine,hum.Rec.Anlog11$702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$318$39,30830 claims
Boehringer IngelheimJardiance$333$31,59730 claims
Novo NordiskOzempic$1,012$24,53926 claims
PfizerEliquis$349$20,00215 claims
GSKTrelegy Ellipta, Shingrix$251$14,88530 claims
AstraZenecaFarxiga$529$10,89316 claims
AbbVieSynthroid$511$2,02917 claims
Sanofi-aventis U.S. LLCLantus$612$70211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →